Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji K. Kumar, Susanna J. Jacobus, Adam D. Cohen, Matthias Weiss, Natalie Callander, Avina K. Singh, Terri L. Parker, Alexander Menter, Xuezhong Yang, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Aaron Rosenberg, Jeffrey A. Zonder, Edward Faber, Sagar Lonial, Kenneth C. Anderson, Paul G. Richardson, Robert Z. Orlowski, Lynne I. WagnerS. Vincent Rajkumar
Dive into the research topics of 'Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial'. Together they form a unique fingerprint.